Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Platelet-Derived Microvesicles Reverse the Lupus Anticoagulant Effect and Are More Potent then Synthetic Phospholipids in Supporting Thrombin Generation in Antiphospholipid Syndrome

Cuicui Bai, PhD, Saartje Bloemen, PhD, Xiao Xuan Wu, MD, Ruchika Goel, MD MPH, Sheshadri Narayanan, Bas De Laat, MD, PhD, Jacob H. Rand, MD PhD, Ljiljana V. Vasovic, MD

Blood (2018) 132 (Supplement 1): 3790.

https://doi.org/10.1182/blood-2018-99-113486

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Laura E. Finn, MD, Moshe Levy, MD, Johnnie J. Orozco, MD PhD, Jae H. Park, MD, Ehab Atallah, MD, Michael Craig, MD, Alexander E. Perl, MD, David A. Scheinberg, MDPhD, Dragan Cicic, MD, Gregory Richard Bergonio, MSc, BSN, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2017) 130 (Supplement 1): 2638.

https://doi.org/10.1182/blood.V130.Suppl_1.2638.2638

Published: 2017

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H. Park, MD, B. Douglas Smith, MD, Moshe Yair Levy, MD, Elihu H. Estey, MD, Alexander E. Perl, MD, Hagop Kantarjian, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 3794.

https://doi.org/10.1182/blood.V126.23.3794.3794

Published: 2015

Journal Articles

Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma

Raphaël Szalat, MD, Mehmet Kemal Samur, PhD, Alice Cleynen, PhD, Anne Calkins, Matija Dreze, Yu-Tzu Tai, PhD, Stephane Minvielle, Herve Avet-Loiseau, Kenneth C. Anderson, MD, Jean-Paul Fermand, Jean-Bernard Lazaro, PhD, Nikhil C. Munshi, MD

Blood (2015) 126 (23): 4187.

https://doi.org/10.1182/blood.V126.23.4187.4187

Published: 2015

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H Park, MD, B. Douglas Smith, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, Richard L. Wahl, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2014) 124 (21): 5293.

https://doi.org/10.1182/blood.V124.21.5293.5293

Published: 2014

Journal Articles

Aldosterone Promotes Inflammation and Endothelial Cell-Sickle Cell Adhesion: Potential for a New Therapeutic Target in Sickle Cell Disease

Wilbur Aaron Lam, MD, PhD, Wendy R Hansen, PhD, James Huang, MD, William Mentzer, MD, Bertram Harold Lubin, MD, Frans A. Kuypers, PhD, Daniel A. Fletcher, PhD

Blood (2008) 112 (11): 125.

https://doi.org/10.1182/blood.V112.11.125.125

Published: 2008

NARROW

Platelet-Derived Microvesicles Reverse the Lupus Anticoagulant Effect and Are More Potent then Synthetic Phospholipids in Supporting Thrombin Generation in Antiphospholipid Syndrome

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Aldosterone Promotes Inflammation and Endothelial Cell-Sickle Cell Adhesion: Potential for a New Therapeutic Target in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Platelet-Derived Microvesicles Reverse the Lupus Anticoagulant Effect and Are More Potent then Synthetic Phospholipids in Supporting Thrombin Generation in Antiphospholipid Syndrome

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Aldosterone Promotes Inflammation and Endothelial Cell-Sickle Cell Adhesion: Potential for a New Therapeutic Target in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only